Shares of Hims & Hers, which has clashed with Novo Nordisk over its sales of compounded glucagon-like peptide inhibitors, rose slightly in the wake of the report, and have more than doubled in value ...

One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly ( LLY -5.50%) closed today's trading session down by almost 6% in value, ...

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription ...

Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its ...

Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase ...

Novo Nordisk stock (NVO) (DK:NOVO.B) slumped 21.83% to fall to a new three-year low. It was the stock's worst daily loss since a 26.15% fall on Oct. 19, 1987. It's fallen 24.77% over the past two days ...

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...